Brief: Memphasys Says Potential Expedited FDA Pathway To US IVF Market
25/09/2026 02:10
BRIEF-Memphasys Says Potential Expedited FDA Pathway To US IVF Market Sept 25 (Reuters) - Memphasys Ltd MEM.AX:
POTENTIAL EXPEDITED FDA PATHWAY TO US IVF MARKET
BOARD IDENTIFIES POTENTIAL EXPEDITED FDA PATHWAY FOR FELIX REPLACING DE NOVO
TO UNDERTAKE PRE-SUBMISSION ENGAGEMENT WITH FDA FOR FELIX REGULATORY PATHWAY
Further company coverage: MEM.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Memphasys
See all newsBrief: Memphasys Receives A$3.5 Million From Peters Investments
Brief: Memphasys Says Potential Expedited FDA Pathway To US IVF Market
Brief: Memphasys Secures 3-Year Felix Agreement With Invido For A$674,000 Minimum Purchases
Australia's Memphasys soars on signing exclusive commercialisation agreement with NOVIVITAE
Brief: Memphasys Says Vietnamese Registration For Felix System Has Been Achieved In August 2026